Company
Every investor coverage indicates participated in a round SYNthesis Research raised.
Companies SYNthesis Research acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
Stories naming SYNthesis Research. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Profile of scientist-entrepreneur Andrew Wilks covering the GSK sale of his cancer molecule, his SYNthesis BioVentures fund's family-office backers, and portfolio plays including Aculeus Therapeutics.
The venture firm's newsletter records a A$2.25m SAFE investment in Aculeus Therapeutics, its fund's second deal, and outlines the immunology-oncology pipeline and long-standing individual backers behind the biotech.